- |||||||||| DYV700 / Dyve Biosciences
[VIRTUAL] Dyve Biosciences () - May 31, 2021 - Abstract #BIO2021BIO_320;
Dyve is a clinical stage biotech company with its lead asset, DYV700, currently completing a 20- center, 100-patient, Phase 2 clinical study for the treatment of acute gout...It combines the fast onset of action of an injection with the extended duration and bioavailability of an oral pill – creating ideal PK/PD parameters and an optimal drug profile. Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs.
- |||||||||| DYV700 / Dyve Biosci
Enrollment status: Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS) (clinicaltrials.gov) - Feb 27, 2020
P2, N=300, Recruiting,
Dyve has a robust internal pipeline of novel drugs and a research collaboration in place with a Top 10 Pharmaceutical Company on a separate set of target NCEs. Enrolling by invitation --> Recruiting
|
